uniQure (NASDAQ:QURE) Director Sells $526,526.10 in Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 11,685 shares of uniQure stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the sale, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. This trade represents a 21.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

• On Monday, June 15th, Madhavan Balachandran sold 10,000 shares of uniQure stock. The stock was sold at an average price of $27.85, for a total transaction of $278,500.00.
• On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.

uniQure Stock Performance

NASDAQ QURE opened at $46.29 on Monday. The business has a 50 day simple moving average of $24.74 and a two-hundred day simple moving average of $22.17. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The stock has a market capitalization of $2.92 billion, a PE ratio of -13.30 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, research analysts predict that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on QURE shares. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $25.00 to $65.00 in a research note on Thursday. HC Wainwright reiterated a “buy” rating on shares of uniQure in a report on Thursday. Chardan Capital increased their price objective on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $58.92.

Hedge Funds Weigh In On uniQure

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of uniQure by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc raised its holdings in uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares during the last quarter. Quinn Opportunity Partners LLC purchased a new position in uniQure during the third quarter worth approximately $6,281,000. Farallon Capital Management LLC boosted its position in shares of uniQure by 3,935.7% during the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $8,599,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.